Volume 11, Number 8—August 2005
Dispatch
Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
Table A3
Neuraminidase efficacy and related parameters included in the model
Variable | Point estimate | Range | Reference |
---|---|---|---|
Efficacy of antiviral prophylaxis* | |||
Preexposure prophylaxis† | 71 | 57–85 | 24,28 |
Postexposure prophylaxis† | 36 | 25–47 | 29 |
Efficacy of antiviral therapy | |||
% reduction in hospitalization | 59 | 30–70 | 27 |
% reduction in antimicrobial drug use | 63 | 40–80 | 26 |
Reduction in lost work days under treatment | 1 | 0.5–1.5 | 26 |
Annual probability of pandemic (%) | 3 | 1–10 | Assumed |
% patients seeking medical care within 48 hours | 80 | 70–90 | 16 |
*Efficacy presented as percent reduction of attack rate.
†Based on a meta-analysis of 2 studies (see text for details).
References
- WHO consultation on priority public health interventions before and during an influenza pandemic, Geneva, 16–18 March 2004. Wkly Epidemiol Rec. 2004;79:107–8.PubMedGoogle Scholar
- Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659–71. DOIPubMedGoogle Scholar
- World is ill-prepared for "inevitable" flu pandemic. Bull World Health Organ. 2004;82:317–8.PubMedGoogle Scholar
- Cohen Y. Tamiflu pharmaco-economic dossier, part C: evaluation of influenza cost of illness in Israel. Natanya (Israel): Quintiles Israel; 2000. p. 1–46.
- Statistical abstract of Israel 2003, no. 54. Jerusalem: Israel Central Bureau of Statistics; 2003.
- Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623–33. DOIPubMedGoogle Scholar
- McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs. 2001;61:263–83. DOIPubMedGoogle Scholar
- Lazzari S, Stohr K. Avian influenza and influenza pandemics. Bull World Health Organ. 2004;82:242.PubMedGoogle Scholar
- Balicer RD, Huerta M, Grotto I. Tackling the next influenza pandemic. BMJ. 2004;328:1391–2. DOIPubMedGoogle Scholar
- Blendon RJ, Benson JM, DesRoches CM, Raleigh E, Taylor-Clark K. The public's response to severe acute respiratory syndrome in Toronto and the United States. Clin Infect Dis. 2004;38:925–31. DOIPubMedGoogle Scholar
- Finland says it's to buy stocks of Roche's Tamiflu. Reuters Health Information [serial online], Mar 10, 2005 [cited 15 May 2005]. Available from http://www.influenza.com/
- Coombes R. UK stocks up on antiviral drug to tackle flu outbreak. BMJ. 2005;330:495. DOIPubMedGoogle Scholar
- Statistical abstract of Israel 2003, no. 54. Jerusalem: Israel Central Bureau of Statistics; 2003.
- Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659–71. DOIPubMedGoogle Scholar
- Cohen Y. Tamiflu pharmaco-economic dossier, part C: evaluation of influenza cost of illness in Israel. Netanya (Israel): Quintiles Israel; 2000. p. 1–46.
- Saito R, Oshitani H, Masuda H, Suzuki H. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol. 2002;40:84–8. DOIPubMedGoogle Scholar
- Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696–702. DOIPubMedGoogle Scholar
- World Health Organization Department of Communicable Disease Surveillance and Response. Avian influenza A(H5N1)—update 22: first data on patients from Viet Nam, clinical data from Hong Kong 1997, susceptibility of H5N1 viruses to antiviral drugs. 2004 Feb 12 [cited 2005 May 25]. Available from http://www.who.int/csr/don/2004_02_12a/en/
- Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000;48:101–15. DOIPubMedGoogle Scholar
- Israeli Ministry of Health. Oseltamivir phosphate. The Israel Drug Registry. 2005 May 24 [cited 2005 May 25]. Available from http://www.health.gov.il/units/pharmacy/trufot/PerutTrufa.asp? Reg_Number=118%2079%2029952%2000&safa=e
- Kirkbride H, Watson J. A review of the use of neuraminidase inhibitors for prophylaxis of influenza. NI paper for communicable disease and public health (CDPH). UK Health Protection Agency. 2002 Sep 27 [cited 2005 May 25]. Available from http://www.hpa.org.uk/infections/publications/pdf/Neuramindase.pdf
- Centers for Disease Control and Prevention. Antiviral agents for influenza: background information for clinicians. 2003 Dec 16 [cited 2005 May 25]. Available from http://www.cdc.gov/flu/professionals/pdf/antiviralsbackground.pdf
- Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336–43. DOIPubMedGoogle Scholar
- Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016–24. DOIPubMedGoogle Scholar
- Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235–41. DOIPubMedGoogle Scholar
- Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–72. DOIPubMedGoogle Scholar
- Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999;282:31–5. DOIPubMedGoogle Scholar
- Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623–33. DOIPubMedGoogle Scholar
- Oxford JS, Bossuyt S, Balasingam S, Mann A, Novelli P, Lambkin R. Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clin Microbiol Infect. 2003;9:1–14. DOIPubMedGoogle Scholar
- Breslow NE. Elementary methods of cohort analysis. Int J Epidemiol. 1984;13:112–5. DOIPubMedGoogle Scholar
- Fleiss JL. The measurement of interrater agreement. In Fleiss JL, editor. Statistical methods for rates and proportions. New York: Wiley; 1981. p. 212–36.
- Kleinbaum DG, Kupper LL, Morganstern H. Stratified analysis. In: Epidemiologic research. New York: Van Nostrand Reinhold; 1982. p. 321–76.
- Abramson JH, Gahlinger PM. Computer programs for epidemiologists: PEPI Version 4.0. Salt Lake City (UT): Sagebrush Press; 2001.
- Balicer RD, Huerta M, Grotto I. Tackling the next influenza pandemic. BMJ. 2004;328:1391–2. DOIPubMedGoogle Scholar